In this study, we described two NSCLC cases in which rare ALK fusions, striatin (STRN)‐ALK and LIM domain only protein 7 (LMO7)‐ALK, as identified by next‐generation sequencing (NGS), showed unfavourable responses to alectinib treatment. This evidence concerns the gene ALK and non-small cell lung carcinoma.